ArriVent BioPharma, Inc. AVBP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$43.32M+32.7% | -$35.54M-72.3% | -$34.98M-70.1% | -$31.4M-43.5% | -$64.39M-270% | ||
| -$559K+26.1% | -$756.5K— | -$756.5K— | -$756.5K— | -$756.5K— | ||
| $5.49M+142% | $3.22M+238% | $3.72M+329% | $3.31M+333% | $2.27M+263% | ||
| $2.81M+382% | —— | $1.87M+124% | —— | $582K+256% | ||
| -$3.83M+21.5% | $4.43M+49.0% | $91K-95.9% | $7.03M+228% | -$4.88M-407% | ||
| $2.56M+61.0% | $0+100% | $6.49M+2,278% | $4.76M+2,033% | $1.59M+213% | ||
| $47K+1,275% | -$5K-25.0% | -$6K— | -$6K— | -$4K-140% | ||
| -$41.89M+38.4% | -$30.66M-89.8% | -$35.8M-119% | -$26.12M-36.9% | -$68.01M-265% | ||
| $64.38M+556% | $151.18M+211% | $90.37M+86.2% | $21.57M-55.6% | $9.82M-79.8% | ||
| $67.97M+45.7% | $79.98M+18,730% | $39.61M+9,225% | $35.48M+8,253% | $46.64M+10,880% | ||
| $3.58M-90.3% | -$71.2M-48.0% | -$50.76M-5.5% | $13.91M+129% | $36.82M+177% | ||
| $54.72M+740% | $34.66M— | $167.6M-9.8% | $0— | $6.52M-96.5% | ||
| $54.87M+712% | $34.73M+63,036% | $86.47M+16,183% | $75.11M+20,593% | $6.76M-96.4% | ||
| $16.56M+168% | -$67.13M+67.8% | -$93K— | $62.9M— | -$24.43M-115% | ||
| $2.81M+382% | —— | $1.87M+124% | —— | $582K+256% | ||
| $47K+1,275% | -$5K-25.0% | -$6K— | -$6K— | -$4K-140% | ||
| -$37K— | —— | —— | —— | —— | ||
| $2.56M+61.0% | $0+100% | $6.49M+2,278% | $4.76M+2,033% | $1.59M+213% | ||
| $67.97M+45.7% | $79.98M+18,730% | $39.61M+9,225% | $35.48M+8,253% | $46.64M+10,880% | ||
| —— | $17K— | —— | $303K— | $50K— | ||
| $47K+1,275% | -$5K-25.0% | -$6K— | -$6K— | -$4K-140% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ArriVent BioPharma, Inc.'s cash flow data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.